The call ran from 5:01 PM to 5:49 PM IST (48 min).
Key takeaways
Record Q2 FY27 revenue of about ₹376 Cr (+28% QoQ), but gross margin fell 4ppt to 49% on West Asia raw-material costs. Management gave no numerical forward guidance; margin recovery depends on price hikes from Q3.
| Revenue growth | Q2 revenue ₹376 Cr, +28% QoQ; H1 +29% YoY. |
|---|---|
| Margins | Q2 gross margin 49%, down 4ppt QoQ; H1 51%, down 3ppt YoY. |
| Order book | Not quantified; management cites strong visibility from innovator relationships. |
| Demand visibility | Management cites good order visibility; no quantified outlook given. |
| Management confidence | Balanced-to-defensive; repeatedly declined forward numerical guidance. |
Growth
Q2 +28% QoQ; contrast media +25%, PI/API +52%, sweetener -30%. H1 revenue ₹669 Cr, +29% YoY.
Outlook
No numerical guidance given. Phase-one WISAC capex ~₹1,000 Cr, timing unspecified; Mahad unit on stream H2 FY27.
Risks
Gross margin down 4ppt QoQ to 49%; price hikes only from Q3; crude-linked costs unpredictable; no growth guidance.
Last quarter's promises, checked
Delivered
- Hyderabad R&D 'operational this month' → operational (= BEAT)
- PI/API 'strong order book, 3–4 qtrs visibility' → PI/API +52% QoQ (= BEAT)
Partly delivered
- ~₹30 Cr goods-in-transit to book in Q2 → uplift not quantified (= PARTIAL)
- 2 high-conviction programs due FY27–28 → still clinical, unquantified (= PARTIAL)
Missed
- Raw-material cost pass-through 'with a few-quarter gap' → GM 53%→49%, hikes only from Q3 (= MISS)
- Mahad 'slightly ahead of' H2 FY27 schedule → on stream H2 FY27 (= MISS)
Summary by ALFA Finder, written with AI assistance from our own recording of the call, published . Open it on ALFA Filings ›
The results behind this call
Blue Jet Healthcare Q2 FY27 Results: Net Profit ₹102.5 Cr, Up 96.7% YoY
Blue Jet Healthcare reported standalone financial results for the quarter ended September 30, 2026. Revenue from operations reached Rs.375.74 Crore with a net profit of Rs.102.52 Crore.
- Key figure
- Net profit ₹102.5 Cr · +96.7% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
R&D center in Hyderabad operational by Sept’26; Vizag project commenced; raised ₹8,000mn via QIP for expansion.
Growth they described
Revenue grew 25% QoQ; EBITDA increased 38% QoQ to ₹981mn with 33% margins. YoY revenue declined 17% due to lower PI sales.
Call details
| Company | Blue Jet Healthcare Limited |
|---|---|
| NSE symbol | BLUEJET |
| ISIN | INE0KBH01020 |
| Call | Q2 FY27 earnings call |
| Date | Thursday, 5 November 2026 |
| Time | 5:00 PM IST |
| Length | 48 min |
| Audio | Our stream on YouTube ↗ |
Blue Jet Healthcare Limited: key numbers
- Share price
- ₹553.80
- Market cap
- ₹9,607 Cr
- Revenue (annual)
- ₹947.3 Cr
- Net profit (annual)
- ₹247.8 Cr
- P/E (TTM)
- 33.7×Sector 43.0×
- Promoter holding
- 73.15%-6.66% QoQ
- FII holding
- 0.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Thu, 5 Nov
Today's concalls →
